<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: investment", fill: "#f78fa7"},
{source: "2: investment", target: "2: common stock investors should", fill: "#f78fa7"},
{source: "2: common stock investors should", target: "2: following risk factors as well as", fill: "#f78fa7"},
{source: "2: following risk factors as well as", target: "2: Annual Report ", fill: "#f78fa7"},
{source: "2: Annual Report ", target: "2: registration", fill: "#f78fa7"},
{source: "2: registration", target: "2: the Securities and Exchange Commission", fill: "#f78fa7"},
{source: "2: investment", target: "3: arrangements with", fill: "#9c2542"},
{source: "3: arrangements with", target: "3: significant reduction", fill: "#9c2542"},
{source: "3: arrangements with", target: "9: various types", fill: "#faebd7"},
{source: "9: various types", target: "9: Years Ended December ", fill: "#faebd7"},
{source: "9: Years Ended December ", target: "9: manufacturers", fill: "#faebd7"},
{source: "9: manufacturers", target: "9: distributors", fill: "#faebd7"},
{source: "9: distributors", target: "9: International ", fill: "#faebd7"},
{source: "9: International ", target: "9: principal agreements with", fill: "#faebd7"},
{source: "9: principal agreements with", target: "9: agreement", fill: "#faebd7"},
{source: "9: agreement", target: "9: distribution", fill: "#faebd7"},
{source: "9: distribution", target: "9: international markets", fill: "#faebd7"},
{source: "9: international markets", target: "9: in the Hospira ", fill: "#faebd7"},
{source: "9: various types", target: "12: avoid future", fill: "#00ff7f"},
{source: "12: avoid future", target: "12: inventory reductions", fill: "#00ff7f"},
{source: "12: inventory reductions", target: "12: sharp declines", fill: "#00ff7f"},
{source: "12: avoid future", target: "16: conditional exclusive rights", fill: "#002395"},
{source: "16: conditional exclusive rights", target: "16: exclusive rights", fill: "#002395"},
{source: "16: exclusive rights", target: "16: systems under", fill: "#002395"},
{source: "16: systems under", target: "16: accounts", fill: "#002395"},
{source: "16: accounts", target: "16: sell products", fill: "#002395"},
{source: "16: sell products", target: "16: significant price deterioration", fill: "#002395"},
{source: "16: significant price deterioration", target: "16: operations could", fill: "#002395"},
{source: "16: operations could", target: "16: adversely affected", fill: "#002395"},
{source: "16: conditional exclusive rights", target: "25: prices at which", fill: "#a020f0"},
{source: "25: prices at which", target: "25: sell products", fill: "#a020f0"},
{source: "25: sell products", target: "25: depend on", fill: "#a020f0"},
{source: "25: depend on", target: "25: products over", fill: "#a020f0"},
{source: "25: products over", target: "25: manufacture", fill: "#a020f0"},
{source: "25: manufacture", target: "25: same products at", fill: "#a020f0"},
{source: "25: same products at", target: "25: purchase date", fill: "#a020f0"},
{source: "25: prices at which", target: "26: Achieving ", fill: "#deb887"},
{source: "26: Achieving ", target: "26: cost reductions", fill: "#deb887"},
{source: "26: cost reductions", target: "26: manufacturing operations", fill: "#deb887"},
{source: "26: manufacturing operations", target: "26: development", fill: "#deb887"},
{source: "26: development", target: "26: implementation", fill: "#deb887"},
{source: "26: implementation", target: "26: innovative manufacturing", fill: "#deb887"},
{source: "26: innovative manufacturing", target: "26: techniques", fill: "#deb887"},
{source: "26: Achieving ", target: "29: relocation", fill: "#e3ff00"},
{source: "29: relocation", target: "29: manufacturing", fill: "#e3ff00"},
{source: "29: manufacturing", target: "29: assembly operations imposes", fill: "#e3ff00"},
{source: "29: assembly operations imposes", target: "29: operations", fill: "#e3ff00"},
{source: "29: operations", target: "29: significant burden on", fill: "#e3ff00"},
{source: "29: significant burden on", target: "29: resources will", fill: "#e3ff00"},
{source: "29: resources will", target: "29: specialized expertise", fill: "#e3ff00"},
{source: "29: specialized expertise", target: "29: interruption", fill: "#e3ff00"},
{source: "29: interruption", target: "29: which could", fill: "#e3ff00"},
{source: "29: relocation", target: "31: manufacturing", fill: "#ff6700"},
{source: "31: manufacturing", target: "31: San Clemente ", fill: "#ff6700"},
{source: "31: San Clemente ", target: "31: automated assembly", fill: "#ff6700"},
{source: "31: automated assembly", target: "31: Salt Lake City ", fill: "#ff6700"},
{source: "31: Salt Lake City ", target: "31: facility", fill: "#ff6700"},
{source: "31: manufacturing", target: "35: relocation", fill: "#00008b"},
{source: "35: relocation", target: "35: California ", fill: "#00008b"},
{source: "35: California ", target: "35: Connecticut ", fill: "#00008b"},
{source: "35: Connecticut ", target: "35: manufacturing", fill: "#00008b"},
{source: "35: manufacturing", target: "35: facility", fill: "#00008b"},
{source: "35: facility", target: "35: implementation", fill: "#00008b"},
{source: "35: implementation", target: "35: assembly processes", fill: "#00008b"},
{source: "35: assembly processes", target: "35: techniques", fill: "#00008b"},
{source: "35: techniques", target: "35: establishment", fill: "#00008b"},
{source: "35: establishment", target: "35: significant", fill: "#00008b"},
{source: "35: significant", target: "35: burden on", fill: "#00008b"},
{source: "35: burden on", target: "35: management human resources", fill: "#00008b"},
{source: "35: management human resources", target: "35: accounting functions", fill: "#00008b"},
{source: "35: relocation", target: "START_HERE", fill: "#00008b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>General Merchandise Stores</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amazon_(company)">Amazon (company)</a></td>
      <td>Amazon.com, Inc. ( AM-ə-zon) is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assets_under_management">Assets under management</a></td>
      <td>In finance, assets under management (AUM), sometimes called funds under management, measures the total market value of all the financial assets which an individual or financial institution—such as a mutual fund, venture capital firm, or depository institution—or a decentralized network protocol controls, typically on behalf of a client.  These funds may be managed for clients/users or for themselves in the case of a financial institution which has mutual funds or holds its own venture capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Life_Insurance_Corporation">Life Insurance Corporation</a></td>
      <td>Life Insurance Corporation of India (LIC) is an Indian statutory insurance and investment corporation headquartered in the city of Mumbai, India. It is under the ownership of Government of India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Defence_mechanism">Defence mechanism</a></td>
      <td>In psychoanalytic theory, a defence mechanism (American English: defense mechanism), is an unconscious psychological operation that functions to protect a person from anxiety-producing thoughts and feelings related to internal conflicts and outer stressors.Defence mechanisms may result in healthy or unhealthy consequences depending on the circumstances and frequency with which the mechanism is used. Defence mechanisms (German: Abwehrmechanismen) are psychological strategies brought into play by the unconscious mind to manipulate, deny, or distort reality in order to defend against feelings of anxiety and unacceptable impulses and to maintain one's self-schema or other schemas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ivor_Montagu">Ivor Montagu</a></td>
      <td>Ivor Goldsmid Samuel Montagu (23 April 1904, in Kensington, London – 5 November 1984, in Watford) was an English filmmaker, screenwriter, producer, film critic, writer, table tennis player, and Communist activist in the 1930s. He helped to develop a lively intellectual film culture in Britain during the interwar years, and was also the founder of the International Table Tennis Federation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Day_the_Music_Died">The Day the Music Died</a></td>
      <td>On February 3, 1959, American rock and roll musicians Buddy Holly, Ritchie Valens, and "The Big Bopper" J. P. Richardson were killed in a plane crash near Clear Lake, Iowa, together with pilot Roger Peterson. The event later became known as "The Day the Music Died" after singer-songwriter Don McLean referred to it as such in his 1971 song "American Pie".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Decree_nisi">Decree nisi</a></td>
      <td>A decree nisi or rule nisi (from Latin  nisi 'unless') is a court order that will come into force at a future date unless a particular condition is met. Unless the condition is met, the ruling becomes a decree absolute (rule absolute), and is binding.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_American_Free_Trade_Agreement">North American Free Trade Agreement</a></td>
      <td>The North American Free Trade Agreement (NAFTA ; Spanish: Tratado de Libre Comercio de América del Norte, TLCAN; French: Accord de libre-échange nord-américain, ALÉNA) was an agreement signed by Canada, Mexico, and the United States that created a trilateral trade bloc in North America. The agreement came into force on January 1, 1994, and superseded the 1988 Canada–United States Free Trade Agreement between the United States and Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_ID">Facility ID</a></td>
      <td>The facility ID number, also called a FIN or facility identifier, is a unique integer number of one to six digits, assigned by the U.S. Federal Communications Commission (FCC) Media Bureau to each broadcast station in the FCC Consolidated Database System (CDBS) and Licensing and Management System (LMS) databases, among others.\nBecause CDBS includes information about foreign stations which are notified to the U.S. under the terms of international frequency coordination agreements, FINs are also assigned to affected foreign stations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_Reserve">Federal Reserve</a></td>
      <td>The Federal Reserve System (also known as the Federal Reserve or simply the Fed) is the central banking system of the United States of America. It was created on December 23, 1913, with the enactment of the Federal Reserve Act, after a series of financial panics (particularly the panic of 1907) led to the desire for central control of the monetary system in order to alleviate financial crises.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mint_(facility)">Mint (facility)</a></td>
      <td>A mint is an industrial facility which manufactures coins that can be used as currency.\nThe history of mints correlates closely with the history of coins.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ICU MEDICAL INC/DE      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>In evaluating an <font color="blue">investment</font> in our <font color="blue">common stock</font>, investors should consider     carefully, among other things, the following risk factors, as well as the     other information contained in this <font color="blue">Annual Report </font>and our other reports and     <font color="blue">registration</font> statements filed with <font color="blue">the Securities and Exchange Commission</font></td>
    </tr>
    <tr>
      <td>Because we are increasingly <font color="blue">dependent</font> on Hospira for a substantial portion     of our sales, any change in our <font color="blue">arrangements with</font> Hospira causing a decline     in our sales to it could result in a <font color="blue"><font color="blue">significant</font> reduction</font> in our sales and     profits</td>
    </tr>
    <tr>
      <td>We have <font color="blue">steadily increased</font> our sales <font color="blue">to Hospira </font>in <font color="blue">recent years</font>, except for     2004 when sales <font color="blue">to Hospira </font><font color="blue">declined as</font> Hospira reduced its <font color="blue">inventories</font> of     our products</td>
    </tr>
    <tr>
      <td>As a result, we <font color="blue">depend on</font> Hospira for a <font color="blue">high percentage</font> of our     sales</td>
    </tr>
    <tr>
      <td>Sales <font color="blue">to Hospira </font>increased by approximately dlra75dtta2 million in 2005</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>dlra46dtta7 million of the increase was <font color="blue">attributable</font> to the purchase     of Hospira’s <font color="blue"><font color="blue">Salt Lake City</font> </font>plant and <font color="blue">commencement</font> of <font color="blue">production under</font> a     twenty-year  MCDA  as  of May 1, 2005</td>
    </tr>
    <tr>
      <td>The balance of the increase was     <font color="blue">attributable</font> to the resumption of more <font color="blue">normal levels</font> of CLAVE sales to     Hospira in 2005 after a sharp decline in 2004 described below</td>
    </tr>
    <tr>
      <td>The table     below shows our total revenue to <font color="blue">various types</font> of customers for 2005, 2004     and 2003 (dollars in millions):                                           11     ______________________________________________________________________                                                <font color="blue">Years Ended <font color="blue">December </font></font>31,                                                                                                  2005                                                                                  2004                                                                                  2003                                                                             Hospira (US)         $                                                                        115dtta0         73       %       $                                                                         39dtta8         53       %       $                                                                         71dtta3         67       %       Other <font color="blue"><font color="blue">manufacture</font>rs</font>         2dtta2         1       %                                                                          1dtta5         2       %                                                                          1dtta5         1       %       Domestic <font color="blue">distributors</font>         24dtta4         16       %                                                                         22dtta4         30       %                                                                         24dtta1         23       %       <font color="blue">International </font><font color="blue">distributors</font>         13dtta0         8       %                                                                          9dtta0         12       %                                                                          5dtta8         5       %       Other revenue         2dtta9         2       %                                                                          2dtta8         3       %                                                                          4dtta6         4       %         Our <font color="blue">principal <font color="blue">agreement</font>s with</font> Hospira are the MCDA, a strategic supply and     <font color="blue">distribution</font> <font color="blue">agreement</font> for most of our other <font color="blue">medical devices</font> in the domestic     and <font color="blue"><font color="blue">international</font> markets</font> and an <font color="blue">agreement</font> to sell Hospira custom IV     systems; the latter two <font color="blue">agreement</font>s extend through 2014</td>
    </tr>
    <tr>
      <td>In 2004, Hospira <font color="blue"><font color="blue">substantially</font> reduced</font> its purchases of CLAVE products     because it was reducing its <font color="blue">inventories</font> of our products</td>
    </tr>
    <tr>
      <td>This caused a     <font color="blue"><font color="blue">significant</font> reduction</font> in our sales and led to a net loss in the third and     <font color="blue">fourth quarters</font> of 2004</td>
    </tr>
    <tr>
      <td>If the steps we have taken to monitor and control     the  amount  of  Hospira’s inventory of CLAVE products to <font color="blue">avoid future</font>     <font color="blue">inventory reductions</font> are not successful we could experience <font color="blue">sharp declines</font>     in sales of CLAVE products <font color="blue">to Hospira </font>in the future</td>
    </tr>
    <tr>
      <td>In the past several years, our prices <font color="blue">to Hospira </font>have <font color="blue">declined by only</font> a     small amount</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">significant</font> decrease</font> in our prices to Hospira, unless     <font color="blue">accompanied by</font> an <font color="blue">offsetting increase</font> in purchasing volume, could have an     adverse effect on our sales and profits</td>
    </tr>
    <tr>
      <td>Under the terms of our <font color="blue">agreement</font>s with Hospira, including the MCDA, we are     <font color="blue">dependent</font>  on  the  marketing and sales efforts of Hospira for a large     percentage of our sales, and Hospira determines the <font color="blue">prices at which</font> the     products that we sell <font color="blue">to Hospira </font>will be sold to its customers</td>
    </tr>
    <tr>
      <td>Hospira has     <font color="blue">conditional <font color="blue">exclusive rights</font></font> to sell CLAVE and our other products as well as     custom  IV  <font color="blue">systems under</font> the SetSource program in many of its major     <font color="blue">accounts</font>, and <font color="blue">exclusive rights</font> to <font color="blue">sell products</font> we produce under the MCDA     If Hospira is unable to maintain its position in the marketplace, or if     Hospira should experience <font color="blue"><font color="blue">significant</font> price deterioration</font>, our sales and     <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Our ability to maintain and increase our <font color="blue">market <font color="blue">penetration</font> depends on</font> the     success of our <font color="blue">arrangement with</font> Hospira and Hospira’s <font color="blue">arrangements with</font>     <font color="blue"><font color="blue">major buying</font> <font color="blue">organizations</font></font> and its ability to renew such arrangements, as to     <font color="blue">which there</font> is no assurance</td>
    </tr>
    <tr>
      <td>Our business could be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font></font>     affected if Hospira terminates its <font color="blue">arrangement with</font> us, negotiates lower     prices, sells more competing products, whether <font color="blue">manufacture</font>d by themselves or     others, or <font color="blue">otherwise alters</font> the nature of its <font color="blue"><font color="blue">relationship with</font> us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we believe that Hospira views us as a source of innovative and profitable     products, there is no assurance that our <font color="blue">relationship with</font> Hospira will     continue in its current form</td>
    </tr>
    <tr>
      <td>In contrast to our <font color="blue">dependence on</font> Hospira, our <font color="blue">principal <font color="blue">competitors</font></font> in the     market for protective IV <font color="blue">connection systems</font> are much larger companies that     dominate the market for IV products and have <font color="blue">broad <font color="blue">product lines</font></font> and large     internal <font color="blue">distribution</font> networks</td>
    </tr>
    <tr>
      <td>In many cases, these <font color="blue">competitors</font> are able to     <font color="blue">establish exclusive relationships with</font> large hospitals, hospital chains,     major  buying  <font color="blue">organizations</font>  and  <font color="blue">home <font color="blue">healthcare providers</font></font> to supply     <font color="blue">substantially</font> all of their <font color="blue">requirements</font> for IV products</td>
    </tr>
    <tr>
      <td>In addition, we     believe that there is a <font color="blue">trend among</font> individual hospitals and <font color="blue">alternate site</font>     healthcare  providers  to  <font color="blue">consolidate into</font> or join large <font color="blue">major buying</font>     <font color="blue">organizations</font> with a view to <font color="blue">standardizing</font> and obtaining <font color="blue">price advantages on</font>     <font color="blue">disposable medical products</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors may limit</font> our ability to gain     market share through our in<font color="blue">dependent</font> dealer network, resulting in continued     <font color="blue">concentration</font> of sales to and <font color="blue">dependence on</font> Hospira</td>
    </tr>
    <tr>
      <td>If we are unable to reduce <font color="blue">substantially</font> the cost of <font color="blue"><font color="blue">manufacturing</font> products</font>     that we will sell <font color="blue">to Hospira </font>under the MCDA, our <font color="blue"><font color="blue">financial performance</font> may</font>     be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">prices at which</font> we <font color="blue">sell products</font> <font color="blue">to Hospira </font>and the gross margins that     we realize under the MCDA <font color="blue">depend on</font> the <font color="blue">cost savings</font> that we expect to     achieve in producing those <font color="blue">products over</font> Hospira’s cost to <font color="blue">manufacture</font> the     <font color="blue">same products at</font> the <font color="blue">purchase date</font></td>
    </tr>
    <tr>
      <td><font color="blue">Achieving </font>substantial <font color="blue">cost reductions</font>     requires moving <font color="blue"><font color="blue">manufacturing</font> <font color="blue">operations</font></font> to lower-cost locations and the     <font color="blue">development</font> and <font color="blue">implementation</font> of <font color="blue">innovative <font color="blue">manufacturing</font></font> and assembly     processes and <font color="blue">techniques</font></td>
    </tr>
    <tr>
      <td>There is no assurance that these <font color="blue">efforts will</font> be     successful</td>
    </tr>
    <tr>
      <td>If we are unable to achieve the <font color="blue">cost savings</font> that we expect, our     profits on products <font color="blue">manufacture</font>d under the MCDA will be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________         The  <font color="blue">relocation</font> of our <font color="blue">manufacturing</font> and <font color="blue">assembly <font color="blue">operations</font> imposes</font> a     <font color="blue"><font color="blue">significant</font> <font color="blue">burden on</font></font> our resources, will require <font color="blue">specialized expertise</font>,     will result in <font color="blue">interruption</font> of production and will require <font color="blue">relocation</font> and     training of personnel ,any of <font color="blue">which could</font> have an adverse effect on our     <font color="blue">operations</font> and financial results</td>
    </tr>
    <tr>
      <td>We intend to relocate substantial portions of our <font color="blue">manufacturing</font> <font color="blue">facilities</font>     by early 2007</td>
    </tr>
    <tr>
      <td>We plan to move all <font color="blue">manufacturing</font> in San Clemente, consisting     of molding and <font color="blue">automated assembly</font>, to our <font color="blue"><font color="blue">Salt Lake City</font> </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We also     plan to move remaining <font color="blue"><font color="blue">manufacturing</font> <font color="blue">operations</font></font> in <font color="blue">Connecticut </font>to the Salt     Lake City <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We plan to move most of the manual assembly <font color="blue">operations</font>     currently performed in <font color="blue"><font color="blue">Salt Lake City</font> </font>to our Ensenada, Mexico <font color="blue">facility</font>,     although we may move some of them to another low-cost location and expect     that some <font color="blue">highly skilled processes may stay</font> in <font color="blue">Salt Lake City</font></td>
    </tr>
    <tr>
      <td>Before the     move to our Ensenada, Mexico <font color="blue">facility</font> we will need to <font color="blue">build additional</font>     production and <font color="blue">warehouse space</font> in that <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Our  performance  under the MCDA, the <font color="blue">relocation</font> of our <font color="blue">California </font>and     <font color="blue">Connecticut </font><font color="blue"><font color="blue">manufacturing</font> <font color="blue">operations</font></font>, the expansion of our Mexico <font color="blue">facility</font>,     the  <font color="blue">implementation</font>  of  new  <font color="blue">manufacturing</font> and <font color="blue">assembly processes</font> and     <font color="blue">techniques</font> and the <font color="blue">establishment</font> of <font color="blue">financial controls</font> impose a <font color="blue">significant</font>     <font color="blue">burden on</font> our <font color="blue">management</font>, human resources, operating and financial and     <font color="blue"><font color="blue">accounting</font> functions</font></td>
    </tr>
    <tr>
      <td>We need to expand our <font color="blue">capabilities</font> in each of these     areas and devote <font color="blue">significant</font> time and effort to <font color="blue">integrating</font> the production     under  the  MCDA  with  our  existing  <font color="blue">operations</font>, all of <font color="blue">which divert</font>     <font color="blue">management</font>’s  <font color="blue">attention from</font> our other <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we may     require additional expertise, capability and <font color="blue">capacity</font> that can best be     obtained through other <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>The molding and <font color="blue">assembly machines</font> are large and require <font color="blue">special handling</font> to     move them</td>
    </tr>
    <tr>
      <td><font color="blue">Installation </font>in a <font color="blue">new location</font> can be very <font color="blue">difficult</font> and require     <font color="blue">specialized engineering expertise</font></td>
    </tr>
    <tr>
      <td>This will tax our <font color="blue">existing resources</font></td>
    </tr>
    <tr>
      <td>At     the same time, we will be attempting to relocate personnel who are important     to  our  <font color="blue">manufacturing</font> processes, and failure to accomplish this could     <font color="blue">substantially</font> hamper the <font color="blue">installation</font> and operation of the equipment in Salt     Lake City</td>
    </tr>
    <tr>
      <td>While we expect to build extra inventory before moving equipment,     and move the equipment in phases and maintain production at both locations     for  a  period  of time, failure to <font color="blue">successfully</font> complete the move and     <font color="blue">installation</font> of the equipment and <font color="blue">critical personnel could</font> cause production     <font color="blue">interruption</font>s and production quality issues <font color="blue">which could</font> <font color="blue"><font color="blue">adversely</font> affect</font> our     sales and income</td>
    </tr>
    <tr>
      <td><font color="blue">Certain  </font>of the manual assembly <font color="blue">operations</font> require expertise that will     require <font color="blue">significant</font> and <font color="blue">ongoing training</font> of the <font color="blue">personnel at</font> the location     performing the assembly</td>
    </tr>
    <tr>
      <td>The products currently made <font color="blue">using manual assembly</font>     in <font color="blue"><font color="blue">Salt Lake City</font> </font>are <font color="blue">different than</font> the products that we currently make in     Mexico</td>
    </tr>
    <tr>
      <td>The transfer of <font color="blue">production will</font> require a <font color="blue">significant</font> transfer of     <font color="blue">knowledge from</font> <font color="blue"><font color="blue">Salt Lake City</font> </font>to the new <font color="blue">manufacturing</font> location, and if this     is not completed <font color="blue">successfully</font>, we could experience production <font color="blue">interruption</font>s     and production quality issues <font color="blue">which could</font> <font color="blue"><font color="blue">adversely</font> affect</font> our sales and     income</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">manage <font color="blue">effective</font>ly</font> our <font color="blue">internal growth</font> or <font color="blue">growth through</font>     <font color="blue"><font color="blue">acquisition</font>s</font> of companies, assets or products, our <font color="blue"><font color="blue">financial performance</font> may</font>     be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We intend to continue to expand our marketing and <font color="blue">distribution</font> capability     internally, by expanding our sales and <font color="blue">marketing staff</font> and resources and may     expand it externally, by <font color="blue"><font color="blue">acquisition</font>s</font> both in the <font color="blue"><font color="blue">United States</font> </font>and foreign     markets</td>
    </tr>
    <tr>
      <td>We may also consider expanding our <font color="blue">product offerings through</font>     further <font color="blue"><font color="blue">acquisition</font>s</font> of companies or <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>We intend to build     <font color="blue">additional production <font color="blue">facilities</font></font> or contract for <font color="blue">manufacturing</font> in markets     outside the <font color="blue"><font color="blue">United States</font> </font>to reduce labor costs and eliminate <font color="blue">transportation</font>     and other costs of shipping finished <font color="blue">products from</font> the <font color="blue"><font color="blue">United States</font> </font>and     Mexico  to  customers  outside  North  America</td>
    </tr>
    <tr>
      <td>The  expansion of our     <font color="blue">manufacturing</font>, marketing, <font color="blue">distribution</font> and <font color="blue">product offerings both internally</font>     and through <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">by contract may</font> place substantial <font color="blue">burdens on</font> our     <font color="blue"><font color="blue">management</font> resources</font> and <font color="blue">financial controls</font></td>
    </tr>
    <tr>
      <td><font color="blue">Decentralization </font>of assembly     and <font color="blue">manufacturing</font> could place further <font color="blue">burdens on</font> <font color="blue">management</font> to manage those     <font color="blue">operations</font>, and maintain <font color="blue">efficiencies</font> and quality control</td>
    </tr>
    <tr>
      <td>The increasing <font color="blue">burdens on</font> our <font color="blue"><font color="blue">management</font> resources</font> and <font color="blue">financial controls</font>     resulting from <font color="blue">internal growth</font> and <font color="blue"><font color="blue">acquisition</font>s</font> could <font color="blue"><font color="blue">adversely</font> affect</font> our     operating results</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue"><font color="blue">acquisition</font>s</font> <font color="blue">may involve</font> a number of special     risks in addition to the <font color="blue">difficult</font>y of <font color="blue">integrating</font> cultures and <font color="blue">operations</font>     and the diversion of <font color="blue">management</font>’s attention, including adverse short-term     <font color="blue">effects on</font> our reported operating results, <font color="blue">dependence on</font> retention, hiring     and training of key personnel, risks associated with unanticipated problems     or <font color="blue">legal liabilities</font> and <font color="blue">amortization</font> of acquired <font color="blue">intangible assets</font>, some or     all  of <font color="blue">which could</font> <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our <font color="blue">operations</font> and     <font color="blue">financial performance</font></td>
    </tr>
    <tr>
      <td>Because we are <font color="blue">dependent</font> on the CLAVE for a major portion of our sales, any     decline in CLAVE <font color="blue">sales could</font> result in a <font color="blue"><font color="blue">significant</font> reduction</font> in our sales     and profits</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________         For 2005, CLAVE products accounted for approximately 40prca of our revenue and     55prca of our revenue including custom IV <font color="blue">systems incorporating</font> a <font color="blue">CLAVE We     </font>depend  heavily  on sales of CLAVE products, especially sales of <font color="blue">CLAVE     </font>products to Hospira</td>
    </tr>
    <tr>
      <td>Most of our CLAVE sales are in the <font color="blue">United States</font>, where     we  expect  our  growth  in sales to moderate in the <font color="blue">future as further</font>     <font color="blue">penetration</font> of <font color="blue">markets available</font> to our <font color="blue">existing customers</font> in the United     States becomes increasingly <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">significant</font> sales increases     for CLAVE products may <font color="blue">depend on</font> increases in sales of custom IV systems     expansion in the <font color="blue"><font color="blue">international</font> markets</font>, which we are <font color="blue">aggressively pursuing</font>,     or <font color="blue">acquisition</font> of <font color="blue">new customers</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We cannot give any     assurance that sales of CLAVE <font color="blue">products will increase indefinitely</font> or that we     can <font color="blue">sustain current profit margins on</font> CLAVE <font color="blue">products indefinitely</font></td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>believes that the success of the CLAVE has motivated, and will     continue to motivate, others to develop one piece <font color="blue">needleless connectors</font></td>
    </tr>
    <tr>
      <td>In     addition to products that emulate the <font color="blue">characteristics</font> of the CLAVE, it is     possible that others could develop <font color="blue">new product concepts</font> and <font color="blue">technologies</font>     that  are  <font color="blue">functionally</font>  equivalent or superior to the CLAVE If other     <font color="blue"><font color="blue">manufacture</font>rs</font> <font color="blue">successfully</font> develop and market <font color="blue">effective</font> products that are     <font color="blue">competitive</font> with CLAVE products, CLAVE <font color="blue">sales could</font> decline as we <font color="blue">lose market</font>     share, and/or we <font color="blue">could encounter sustained price</font> and <font color="blue">profit margin erosion</font></td>
    </tr>
    <tr>
      <td>If our efforts to increase <font color="blue">substantially</font> our <font color="blue"><font color="blue">custom product</font>s</font> business is not     successful or we <font color="blue">cannot increase sales</font> of other products and develop new,     <font color="blue"><font color="blue">commercially</font> successful products</font>, our sales may not continue to grow</td>
    </tr>
    <tr>
      <td>Our <font color="blue">continued success may</font> be <font color="blue">dependent</font> both on the success of our strategic     initiative to increase <font color="blue">substantially</font> our <font color="blue">custom product</font> business and develop     <font color="blue">significant</font>  market  share  on  a  <font color="blue">profitable basis</font> and <font color="blue">on new product</font>     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">total sales</font> of <font color="blue"><font color="blue">custom product</font>s</font> including custom IV     products  and  custom <font color="blue">critical care products</font> reached dlra42dtta6 in 2005, an     increase of 63prca over 2004; however, only 22prca of this increase was in custom     IV products</td>
    </tr>
    <tr>
      <td>The success of our <font color="blue">custom product</font> sales program     will require a <font color="blue">larger increase</font> in sales in the <font color="blue">future than</font> was achieved in     2005  and 2004 and there is no assurance that such an <font color="blue">increase will</font> be     achieved</td>
    </tr>
    <tr>
      <td>Although we are seeking to continue to develop a variety of new     products, there is no assurance that any <font color="blue"><font color="blue">new products</font> will</font> be <font color="blue">commercially</font>     successful or that we will be able to recover the costs of developing,     testing, producing and <font color="blue">marketing such products</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">healthcare product</font>     <font color="blue"><font color="blue">manufacture</font>rs</font>, with financial and <font color="blue">distribution</font> resources <font color="blue">substantially</font>     <font color="blue">greater than ours</font>, have developed and are <font color="blue">marketing products intended</font> to     fulfill the <font color="blue">same functions as</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">sales pose additional risks</font> related to <font color="blue"><font color="blue">competition</font> with larger</font>     <font color="blue"><font color="blue">international</font> companies</font> and <font color="blue">established local companies</font>, our <font color="blue">possibly higher</font>     <font color="blue">cost structure</font>, our ability to open foreign <font color="blue">manufacturing</font> <font color="blue">facilities</font> that     can operate profitably, higher credit risks and <font color="blue">exchange rate risk</font></td>
    </tr>
    <tr>
      <td>We have undertaken a program to increase <font color="blue">significant</font>ly our <font color="blue">international</font>     sales, and have <font color="blue">distribution</font> arrangements in all the <font color="blue">principal countries</font> in     Western Europe, the Pacific Rim and Latin America, and in South Africa</td>
    </tr>
    <tr>
      <td>Currently, we <font color="blue">export from</font> the     <font color="blue"><font color="blue">United States</font> </font>and Mexico most of our products sold <font color="blue">international</font>ly</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">principal <font color="blue">competitors</font></font> in <font color="blue"><font color="blue">international</font> markets</font> are a number of much larger     <font color="blue">companies as well as smaller companies already established</font> in the countries     into which we sell our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">cost structure</font> is often <font color="blue">higher than</font>     that of our <font color="blue">competitors</font> because of the <font color="blue"><font color="blue">relatively</font> high cost</font> of <font color="blue">transporting</font>     product to the <font color="blue">local market as well as</font> our <font color="blue">competitors</font>’ lower local labor     costs in some markets</td>
    </tr>
    <tr>
      <td>For these reasons, among others, we expect to open     <font color="blue">manufacturing</font> <font color="blue">facilities</font> in <font color="blue">foreign locations</font></td>
    </tr>
    <tr>
      <td>There is <font color="blue">no certainty</font> that we     will be able to open local <font color="blue">manufacturing</font> <font color="blue">facilities</font> or that those <font color="blue">facilities</font>     will operate on a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> sales are subject to higher credit <font color="blue">risks than sales</font> in the     United  States</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">distributors</font> are small and may not be well     <font color="blue">capitalized</font></td>
    </tr>
    <tr>
      <td><font color="blue">Payment  </font>terms  are  <font color="blue">relatively</font>  long</td>
    </tr>
    <tr>
      <td>Our prices to our     <font color="blue">international</font> <font color="blue">distributors</font>, outside of Europe, for product shipped to the     <font color="blue">customers from</font> the <font color="blue"><font color="blue">United States</font> </font>or Mexico are set in US dollars, but     their <font color="blue">resale prices</font> are set in their <font color="blue">local currency</font></td>
    </tr>
    <tr>
      <td>A decline in the value     of the <font color="blue">local currency</font> in relation <font color="blue">to the US </font>dollar may <font color="blue"><font color="blue">adversely</font> affect</font>     their ability to <font color="blue">profitably sell</font> in their market the products they buy from     us, and may <font color="blue"><font color="blue">adversely</font> affect</font> their ability to make payment to us for the     products they purchase</td>
    </tr>
    <tr>
      <td>Legal recourse for non-payment of <font color="blue">indebtedness may</font>     be uncertain</td>
    </tr>
    <tr>
      <td>In 2003, we acquired a small <font color="blue">manufacture</font>r of IV systems in northern Italy,     and have since transferred our European <font color="blue">distribution</font> to this subsidiary</td>
    </tr>
    <tr>
      <td>Sales and most other <font color="blue"><font color="blue">transaction</font>s</font> by this subsidiary are <font color="blue">denominated</font> in     Euros</td>
    </tr>
    <tr>
      <td>As the subsidiary increases in size, a decline in the value of the     Euro in relation <font color="blue">to the US </font><font color="blue">dollar could</font> have an adverse effect on our     reported operating results</td>
    </tr>
    <tr>
      <td>There is <font color="blue">no assurance as</font> to the growth of this     subsidiary or its future operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Continuing </font>pressures to reduce healthcare costs may <font color="blue"><font color="blue">adversely</font> affect</font> our     prices</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot reduce</font> <font color="blue">manufacturing</font> costs of                                           14     ______________________________________________________________________         existing  and <font color="blue">new products</font>, our sales may not continue to grow and our     <font color="blue"><font color="blue"><font color="blue">profitability</font> may</font> decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font>awareness of healthcare costs, public interest in healthcare     reform and <font color="blue">continuing pressure from</font> Medicare, Medicaid and other payers to     <font color="blue">reduce costs</font> in the <font color="blue">healthcare industry</font>, as well as increasing <font color="blue">competition</font>     from other protective products, could make it more <font color="blue">difficult</font> for us to sell     our <font color="blue">products at current prices</font></td>
    </tr>
    <tr>
      <td>In the event that the market will not accept     current prices for our products, our sales and profits could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We believe that our ability to increase our market share and     operate profitably in the <font color="blue">long term may depend</font> in part on our ability to     reduce  <font color="blue">manufacturing</font>  costs  on  a per unit <font color="blue">basis through high volume</font>     <font color="blue">production using highly automated molding</font> and <font color="blue">assembly systems</font></td>
    </tr>
    <tr>
      <td>If we are     unable to reduce unit <font color="blue">manufacturing</font> costs, we may be unable to increase our     market  share  for  CLAVE products or <font color="blue">lose market</font> share to <font color="blue">alternative</font>     products, including <font color="blue">competitors</font>’ products</td>
    </tr>
    <tr>
      <td>Similarly, if we <font color="blue">cannot reduce</font>     unit <font color="blue">manufacturing</font> costs of <font color="blue">new products</font> as production volumes increase, we     may not be able to sell <font color="blue">new products</font> profitably or gain any <font color="blue">meaningful</font>     market share</td>
    </tr>
    <tr>
      <td>Any of these results would <font color="blue"><font color="blue">adversely</font> affect</font> our future results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are unable to compete <font color="blue">successfully</font> on the basis of <font color="blue">product innovation</font>,     quality, convenience, price and <font color="blue">rapid delivery with larger companies</font> that     have <font color="blue">substantially</font> greater resources and larger <font color="blue">distribution</font> networks, we     may be unable to maintain market share, in which case our sales may not grow     and our <font color="blue"><font color="blue">profitability</font> may</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>The market for IV products is intensely <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We believe that our     ability to compete depends upon continued <font color="blue">product innovation</font>, the quality,     convenience  and  <font color="blue">re<font color="blue">liability</font></font>  of our products, access to <font color="blue">distribution</font>     channels, patent protection and pricing</td>
    </tr>
    <tr>
      <td>The ability to compete <font color="blue">effective</font>ly     depends  on  our ability to differentiate our <font color="blue">products based on safety</font>     features, product quality, cost <font color="blue">effective</font>ness, ease of use and convenience,     as well as our ability to perceive and respond to changing customer needs</td>
    </tr>
    <tr>
      <td>We  encounter  <font color="blue">significant</font>  <font color="blue">competition</font> in our <font color="blue">markets both from</font> large     <font color="blue">established medical</font> device <font color="blue"><font color="blue">manufacture</font>rs</font> and <font color="blue">from smaller companies</font></td>
    </tr>
    <tr>
      <td>Many of     these firms have introduced <font color="blue">competitive</font> products with protective features     not provided by the <font color="blue">conventional</font> products and methods they are intended to     replace</td>
    </tr>
    <tr>
      <td>Most of our current and prospective <font color="blue">competitors</font> have economic and     other resources <font color="blue">substantially</font> <font color="blue">greater than ours</font> and are well established as     suppliers to the <font color="blue">healthcare industry</font></td>
    </tr>
    <tr>
      <td>Several large, established <font color="blue">competitors</font>     offer <font color="blue">broad <font color="blue">product lines</font></font> and have <font color="blue">been successful</font> in obtaining full-line     <font color="blue">contracts with</font> a <font color="blue">significant</font> number of hospitals to supply all of their IV     product <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>There is no assurance that our <font color="blue">competitors</font> will not     <font color="blue">substantially</font> increase resources devoted to the <font color="blue">development</font>, <font color="blue">manufacture</font> and     marketing  of  products  <font color="blue">competitive</font> with our products</td>
    </tr>
    <tr>
      <td>The successful     <font color="blue">implementation</font> of such a <font color="blue">strategy by one</font> or more of our <font color="blue">competitors</font> could     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> us</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">significant</font>ly expand our sales of custom IV systems,     or <font color="blue">critical care products</font>, if we are unable to lower <font color="blue">manufacturing</font> costs,     price our products <font color="blue">competitive</font>ly and <font color="blue">shorten delivery times</font> <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>We believe that the success of our IV systems <font color="blue">operations</font> will <font color="blue">depend on</font>     our ability to lower per unit <font color="blue">manufacturing</font> costs and price our products     <font color="blue">competitive</font>ly and on our ability to shorten <font color="blue">significant</font>ly the time from     customer order to delivery of finished product, or both</td>
    </tr>
    <tr>
      <td>To <font color="blue">reduce costs</font>, we     have moved labor intensive assembly <font color="blue">operations</font> to our <font color="blue">facility</font> in Mexico</td>
    </tr>
    <tr>
      <td>To     <font color="blue">shorten delivery times</font>, we have developed <font color="blue">proprietary systems</font> for order     processing,  materials  handling, tracking, labeling and invoicing and     <font color="blue">innovative procedures</font> to <font color="blue">expedite assembly</font> and <font color="blue">distribution</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>of  these  systems  and  procedures require continuing <font color="blue">enhancement</font> and     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>There is a <font color="blue">possibility</font> that our systems and <font color="blue">procedures may</font> not     continue to be adequate and meet their <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We plan to introduce many of the systems and procedures that we have used in     our IV systems <font color="blue">operations</font> into the production of <font color="blue">critical care products</font></td>
    </tr>
    <tr>
      <td>If  we are unable to do this <font color="blue">successfully</font>, we may not be successful in     <font color="blue">increasing sales</font> of <font color="blue">critical care products</font></td>
    </tr>
    <tr>
      <td>If demand for our CLAVE products were to decline <font color="blue">significant</font>ly, we might not     be able to recover the cost of our <font color="blue">expensive automated molding</font> and assembly     equipment and tooling, <font color="blue">which could</font> have an adverse effect on our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">production tooling</font> is <font color="blue">relatively</font> expensive, with each “module,” which     consists of an <font color="blue">automated assembly</font> machine and the molds and <font color="blue">molding machines</font>     which mold the components, costing several million dollars</td>
    </tr>
    <tr>
      <td>Most of the     modules are for the CLAVE and the integrated Y-CLAVE If the demand for     either of these products changes <font color="blue">significant</font>ly, as might happen with the     loss of a customer or a change in <font color="blue">product mix</font>, it might be <font color="blue">necessary</font> for us     to account for the <font color="blue">impairment</font> in value of the <font color="blue">production tooling</font> because its     cost may not be <font color="blue">recovered through production</font> of <font color="blue">saleable product</font></td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________         If we were to experience <font color="blue">problems with</font> our highly complex <font color="blue">manufacturing</font> and     <font color="blue">automated assembly</font> processes, as we have at times in the past, or if we     cannot obtain <font color="blue">additional custom tooling</font> and <font color="blue">equipment on</font> a <font color="blue">timely enough</font>     basis to meet demand for our products, we might be unable to increase our     sales or <font color="blue">might lose customers</font>, in which case our <font color="blue">sales could</font> decline</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> <font color="blue">substantially</font> all of our product components, except for     standard <font color="blue">components which</font> are <font color="blue">available as</font> commodity items, and assemble     them into finished products</td>
    </tr>
    <tr>
      <td><font color="blue">Automated </font>assembly of <font color="blue">components into</font> finished     <font color="blue">products involves complex procedures</font> requiring <font color="blue">highly sophisticated assembly</font>     <font color="blue">equipment which</font> is custom designed, engineered and <font color="blue">manufacture</font>d for us</td>
    </tr>
    <tr>
      <td>As a     result of the <font color="blue">critical performance criteria</font> for our products, we have at     times experienced <font color="blue">problems with</font> the <font color="blue">design criteria</font> for or the molding or     assembly of our products</td>
    </tr>
    <tr>
      <td>We believe that we have resolved all design,     <font color="blue">manufacturing</font> and assembly <font color="blue">problems with</font> respect to products <font color="blue">manufacture</font>d in     <font color="blue">San Clemente </font>and Connecticut</td>
    </tr>
    <tr>
      <td>We are continuing our <font color="blue">assessment</font> of design,     <font color="blue">manufacturing</font> and assembly <font color="blue">operations</font> at the <font color="blue"><font color="blue">Salt Lake City</font> </font><font color="blue">facility</font> and     that <font color="blue">assessment</font> has resulted in changes and will result in future changes,     some of which may be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>There is no assurance that <font color="blue">operations</font> will     not be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by unanticipated <font color="blue">problems with</font> current or future     products</td>
    </tr>
    <tr>
      <td>We have expanded our <font color="blue">manufacturing</font> <font color="blue">capacity</font> <font color="blue">substantially</font> in <font color="blue">recent years</font>,     and we expect <font color="blue">continuing expansion will</font> be <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>Molds and automated     <font color="blue">assembly machines</font> <font color="blue">generally</font> have a long lead-time with vendors, often six     months or longer</td>
    </tr>
    <tr>
      <td><font color="blue">Inability </font>to secure such tooling in a <font color="blue">timely manner</font>, or     <font color="blue">unexpected increases</font> in production demands, could cause us to be unable to     meet  customer  orders</td>
    </tr>
    <tr>
      <td>Such  <font color="blue">inability could</font> cause customers to seek     <font color="blue">alternative</font>s to our products</td>
    </tr>
    <tr>
      <td>We are increasingly <font color="blue">dependent</font> on <font color="blue">manufacturing</font> in Mexico</td>
    </tr>
    <tr>
      <td>Any political or     <font color="blue">economic <font color="blue">disruption</font></font> <font color="blue">in Mexico </font>or a change in the <font color="blue">local economy could</font> have an     adverse effect on our <font color="blue">operations</font>         We continue to expand our production in Mexico</td>
    </tr>
    <tr>
      <td>Most of the material we use in     <font color="blue">manufacturing</font> is <font color="blue">imported into</font> Mexico, and <font color="blue">substantially</font> all the production     <font color="blue">in Mexico </font>is exported</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our ability to move goods across the     <font color="blue">border quickly</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">disruption</font> in the free flow of goods across the border     could have an adverse effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">As of January </font>31, 2006, we employed 573 people in our plant in Ensenada,     Mexico, and expect this to increase in the future</td>
    </tr>
    <tr>
      <td>Business activity in the     Ensenada area is expanding <font color="blue">significant</font>ly, providing increasing employment     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>This could have an adverse effect on our ability to hire or     retain  <font color="blue">necessary</font>  personnel and <font color="blue">increase amounts</font> we <font color="blue">must pay them</font></td>
    </tr>
    <tr>
      <td>We     continue to take steps to compete for <font color="blue">labor through attractive employment</font>     <font color="blue">conditions</font> and benefits, but there is no assurance that these steps will     continue to be successful or that we will not <font color="blue">face increasing labor costs</font> in     the future</td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in costs of <font color="blue">electricity</font> or <font color="blue">interruption</font>s in electrical service     could have an adverse effect on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We use a <font color="blue">significant</font> amount of <font color="blue">electricity</font> in our molding and automated     assembly <font color="blue">operations</font> in San Clemente, California</td>
    </tr>
    <tr>
      <td>Rates are <font color="blue">substantially</font>     <font color="blue">higher than</font> what they were <font color="blue">six years ago</font>, and there is <font color="blue">no certainty</font> that     they will not <font color="blue">increase further</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, public concerns     are again being raised about possible <font color="blue">interruption</font>s in service because of a     lack of <font color="blue">availability</font> of <font color="blue">electricity</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font> increase in electrical     costs or a <font color="blue">significant</font> <font color="blue">interruption</font> in <font color="blue">service could</font> have an adverse effect     on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We believe that the move of our <font color="blue">San Clemente </font>production     to <font color="blue"><font color="blue">Salt Lake City</font> </font>will <font color="blue">substantially</font> mitigate this risk, but we do not     expect that move to be completed <font color="blue">until approximately</font> the fall of 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in the cost of petroleum-based and natural gas-based products     could have an adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Most of the material used in our products is resins, plastics and other     material that <font color="blue">depend upon oil</font> or <font color="blue">natural gas as</font> their raw material</td>
    </tr>
    <tr>
      <td><font color="blue">Crude     </font>oil and <font color="blue">natural gas supplies continue</font> to be <font color="blue">negatively impacted by</font> the     <font color="blue">recent hurricanes</font> in the Gulf Coast</td>
    </tr>
    <tr>
      <td>Related production and <font color="blue">supply problems</font>     have had a small impact our ability to get <font color="blue">uninterrupted supplies</font> of raw     materials,  which has caused some <font color="blue">minor delay</font> in <font color="blue">deliveries</font> of certain     <font color="blue">products under</font> the MCDA There is no assurance that these <font color="blue">supply problems</font>     will not persist or get worse</td>
    </tr>
    <tr>
      <td>Also, crude oil and <font color="blue">natural gas prices</font> in     2005 are <font color="blue">at record highs</font></td>
    </tr>
    <tr>
      <td>Our suppliers have passed some of their cost     <font color="blue">increases on</font> to us, and if such prices are sustained or <font color="blue">increase further</font>,     our suppliers may pass further cost <font color="blue">increases on</font> to us</td>
    </tr>
    <tr>
      <td>In addition to the     effect on resin prices, <font color="blue">transportation</font> costs have increased because of the     effect of <font color="blue">higher crude oil prices</font>, and at least some of these costs have     <font color="blue">been passed on</font> to us</td>
    </tr>
    <tr>
      <td>Our ability to recover those <font color="blue">higher costs may depend</font>     upon our ability to <font color="blue">raise prices</font> to our customers</td>
    </tr>
    <tr>
      <td>Our inability to <font color="blue">raise prices</font>     in those <font color="blue">circumstances could</font> have an adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________         Because we depend to a <font color="blue">significant</font> extent on our founder for new product     concepts, the loss of his <font color="blue">services could</font> have a material adverse effect on     our business</td>
    </tr>
    <tr>
      <td>We  <font color="blue">depend on</font> Dr</td>
    </tr>
    <tr>
      <td>George A Lopez, our founder, Chairman of the Board,     President  and  Chief  Executive  Officer for <font color="blue">new product concepts</font> and     <font color="blue">manufacturing</font> innovation</td>
    </tr>
    <tr>
      <td>Lopez has conceived <font color="blue">substantially</font> all of our     current and proposed <font color="blue">new products</font> and the systems and procedures to be used     in the custom IV products and their <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>We believe that the     loss of his <font color="blue">services could</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Because we have substantial <font color="blue">cash balances</font> and liquid <font color="blue">investment</font>s in interest     sensitive securities, continued <font color="blue">low interest rates would</font> have an adverse     effect on our <font color="blue">investment</font> income and on our net income</td>
    </tr>
    <tr>
      <td>We have <font color="blue">accumulated</font> a substantial balance of cash and liquid <font color="blue">investment</font>s     <font color="blue">principally</font> through profitable <font color="blue">operations</font> and the exercise of <font color="blue">stock options</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">balances amounted</font> to dlra86dtta7 million at <font color="blue">December </font>31, 2005, of <font color="blue">which over</font>     93prca was invested in <font color="blue">interest sensitive securities</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">securities consist</font>     <font color="blue">principally</font> of <font color="blue">corporate preferred stocks</font> and federal tax-exempt state and     <font color="blue">municipal government debt securities</font></td>
    </tr>
    <tr>
      <td>Short-term interest rates have been the lowest in decades for the past four     years and, <font color="blue">notwithstanding recent increases</font>, are <font color="blue">still low by historic</font>     standards</td>
    </tr>
    <tr>
      <td>In 2000, our <font color="blue">investment</font> income was dlra2dtta1 million on average on     cash and liquid <font color="blue">investment</font>s of approximately dlra43dtta4 million</td>
    </tr>
    <tr>
      <td>For 2005, the     comparable  numbers were approximately dlra2dtta2 million and dlra82dtta5 million,     respectively; <font color="blue">investment</font> income was approximately dlra1dtta8 million lower than it     would have been at the rates in 2000</td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font><font color="blue">low interest rates would</font>     continue to have an adverse effect on our <font color="blue">investment</font> income</td>
    </tr>
    <tr>
      <td>Our business could be <font color="blue">materially</font> and <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if we fail to defend     and enforce our patents, if our products are found to <font color="blue">infringe patents</font> owned     by others or if the cost of <font color="blue">patent <font color="blue">litigation</font> becomes excessive</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">patents on</font> certain products, software and business methods, and     <font color="blue">pending patent applications on</font> other <font color="blue"><font color="blue">intellectual</font> property</font> and <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>There is no assurance, however, that <font color="blue">patents pending will issue</font> or that the     <font color="blue">protection from patents which</font> have issued or may issue in the <font color="blue">future will</font> be     <font color="blue">broad enough</font> to prevent <font color="blue">competitors</font> from introducing similar devices, that     <font color="blue">such patents</font>, if challenged, will be upheld by the courts or that we will be     able to <font color="blue">prove <font color="blue">infringement</font></font> and damages in <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">substantially</font> <font color="blue">dependent</font> upon the <font color="blue">patents on</font> our <font color="blue">proprietary products</font>     such as the CLAVE to prevent others from <font color="blue">manufacturing</font> and selling products     similar to ours</td>
    </tr>
    <tr>
      <td>In April 2005, we settled <font color="blue">litigation</font> against B Braun</td>
    </tr>
    <tr>
      <td>We     have ongoing <font color="blue">litigation</font> against Alaris, a part of Cardinal, for violating     our patents and we are seeking injunctive relief and monetary damages</td>
    </tr>
    <tr>
      <td>Failure to prevail in this <font color="blue">litigation</font> or <font color="blue">litigation</font> we may bring     against others violating our patents in the future could <font color="blue"><font color="blue">adversely</font> affect</font>     our sales</td>
    </tr>
    <tr>
      <td>We  have <font color="blue">faced patent <font color="blue">infringement</font></font> claims related to the CLAVE and the     CLC-2000</td>
    </tr>
    <tr>
      <td>We believe the claims had no merit, and all have <font color="blue">been settled</font> or     dismissed</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also face</font> claims in the future</td>
    </tr>
    <tr>
      <td>From time to time we <font color="blue">become aware</font> of newly issued <font color="blue">patents on</font> <font color="blue">medical devices</font>     which we review to evaluate any <font color="blue"><font color="blue">infringement</font> risk</font></td>
    </tr>
    <tr>
      <td>We are aware of a number     of patents for IV <font color="blue">connection systems</font> that have <font color="blue">been issued</font> to others</td>
    </tr>
    <tr>
      <td>While we believe these <font color="blue">patents will</font> not affect our ability to market our     products,  there is no assurance that these or other issued or pending     <font color="blue">patents might</font> not <font color="blue">interfere with</font> our right or ability to <font color="blue">manufacture</font> and     sell our products</td>
    </tr>
    <tr>
      <td>There  has  been  substantial  <font color="blue">litigation</font>  regarding  patent and other     <font color="blue">intellectual</font>  property  rights  in the medical device industry</td>
    </tr>
    <tr>
      <td><font color="blue">Patent     </font><font color="blue">infringement</font> <font color="blue">litigation</font>, which may be <font color="blue">necessary</font> to <font color="blue">enforce patents issued</font> to     us or to <font color="blue">defend ourselves against</font> claimed <font color="blue">infringement</font> of the rights of     others, can be expensive and <font color="blue">may involve</font> a substantial <font color="blue">commitment</font> of our     <font color="blue">resources which may divert resources from</font> other uses</td>
    </tr>
    <tr>
      <td>Adverse <font color="blue">determinations</font>     in <font color="blue">litigation</font> or <font color="blue">settlements could</font> subject us to <font color="blue">significant</font> liabilities to     third parties, could require us to seek licenses from third parties, could     prevent us from <font color="blue">manufacturing</font> and selling our products or could fail to     prevent <font color="blue">competitors</font> from <font color="blue"><font color="blue">manufacturing</font> products</font> similar to ours</td>
    </tr>
    <tr>
      <td>Any of     these results could <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>Our ability to market our products in the <font color="blue"><font color="blue">United States</font> </font>and other countries     may be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if our products or our <font color="blue">manufacturing</font> processes     fail  to  <font color="blue">qualify under applicable standards</font> of the FDA and <font color="blue">regulatory</font>     agencies in other countries</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________         <font color="blue">Government </font>regulation is a <font color="blue">significant</font> factor in the <font color="blue">development</font>, marketing     and <font color="blue">manufacturing</font> of our products</td>
    </tr>
    <tr>
      <td>Our products are subject to <font color="blue">clearance by</font>     the <font color="blue"><font color="blue">United States</font> </font>FDA under a number of statutes including the FDC Act</td>
    </tr>
    <tr>
      <td><font color="blue">Each     </font>of  our current products has qualified, and we anticipate that any new     products we are likely to market will qualify, for clearance under the     FDA’s expedited pre-market notification procedure pursuant to Section 510(k)     of the FDC Act</td>
    </tr>
    <tr>
      <td>There is no assurance, however, that <font color="blue">new products</font> developed     by us or any <font color="blue"><font color="blue">manufacture</font>rs</font> that we might acquire will qualify for expedited     <font color="blue">clearance rather than</font> a more time consuming pre-market approval procedure or     that, in any case, they will receive <font color="blue">clearance from</font> the FDA FDA <font color="blue">regulatory</font>     processes are time consuming and expensive</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties </font>as to the time     required to obtain FDA <font color="blue">clearances</font> or approvals could <font color="blue"><font color="blue">adversely</font> affect</font> the     timing  and expense of <font color="blue">new product introductions</font></td>
    </tr>
    <tr>
      <td>In addition, we must     <font color="blue">manufacture</font>  our  products in <font color="blue">compliance with</font> the FDA’s Quality System     Regulations</td>
    </tr>
    <tr>
      <td>The FDA has <font color="blue">broad discretion</font> in enforcing the FDC Act, and <font color="blue">noncompliance</font>     with the Act could result in a variety of <font color="blue">regulatory</font> actions ranging from     warning letters, product detentions, device alerts or <font color="blue">field corrections</font> to     <font color="blue">mandatory</font>  recalls, seizures, injunctive actions and civil or criminal     penalties</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>determines that we have <font color="blue">seriously violated applicable</font>     <font color="blue">regulations</font>, it could seek to <font color="blue">enjoin us from marketing</font> our products or we     could be otherwise <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by delays or required changes in new     products</td>
    </tr>
    <tr>
      <td>In addition, changes in FDA, or other federal or state, health,     <font color="blue">environmental</font> or safety <font color="blue">regulations</font> or in their application could <font color="blue">adversely</font>     affect our business</td>
    </tr>
    <tr>
      <td>To market our products in the European Community (“EC”), we <font color="blue">must conform</font> to     additional <font color="blue">requirements</font> of the EC and <font color="blue">demonstrate</font> conformance to established     quality standards and applicable <font color="blue">directives</font></td>
    </tr>
    <tr>
      <td>As a <font color="blue">manufacture</font>r that designs,     <font color="blue">manufacture</font>s and markets its own devices, we must comply with the quality     <font color="blue">management</font> standards <font color="blue">of EN ISO </font>9001(1994)/ISO 13485 (1996)</td>
    </tr>
    <tr>
      <td>Those quality     standards  are  similar  to  the  FDA’s Quality System Regulations but     <font color="blue">incorporate</font> the quality <font color="blue">requirements</font> for <font color="blue">product design</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers  </font>of  <font color="blue">medical devices</font> must also be in conformance with EC     Directives such as <font color="blue">Council Directive </font>93/42/EEC (“Medical Device Directive”)     and their applicable annexes</td>
    </tr>
    <tr>
      <td>Those <font color="blue">regulations</font> assure that <font color="blue">medical devices</font>     are both safe and <font color="blue">effective</font> and meet all <font color="blue">applicable established standards</font>     prior to being marketed in the EC Once a <font color="blue">manufacture</font>r and its devices are     in  conformance with the Medical Device Directive, the “CE” Mark maybe     affixed to its devices</td>
    </tr>
    <tr>
      <td><font color="blue">The CE Mark </font><font color="blue">gives devices</font> an <font color="blue">unobstructed entry</font> to     all the member countries of the EC We <font color="blue">cannot assure</font> that we <font color="blue">will continue</font>     to meet the <font color="blue">requirements</font> for <font color="blue">distribution</font> of our products in Europe</td>
    </tr>
    <tr>
      <td><font color="blue">Distribution </font>of our products in other countries may be subject to regulation     in those countries, and there is no assurance that we will obtain <font color="blue">necessary</font>     approvals in countries in which we wants to introduce our products</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims could be costly to defend and <font color="blue">could expose us</font> to     loss</td>
    </tr>
    <tr>
      <td>The use of our <font color="blue">products exposes us</font> to an <font color="blue">inherent risk</font> of product <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Patients, <font color="blue">healthcare workers</font> or <font color="blue">healthcare providers</font> who claim that our     products have resulted in injury could initiate product <font color="blue">liability</font> <font color="blue">litigation</font>     seeking  large  <font color="blue">damage awards <font color="blue">against us</font></font></td>
    </tr>
    <tr>
      <td>Costs of the defense of such     <font color="blue">litigation</font>, even if successful, could be substantial</td>
    </tr>
    <tr>
      <td>We maintain insurance     against product <font color="blue">liability</font> and <font color="blue">defense costs</font> in the amount of dlra10cmam000cmam000 per     occurrence</td>
    </tr>
    <tr>
      <td>There is no assurance that we will <font color="blue">successfully</font> defend claims,     if any, arising <font color="blue">with respect</font> to products or that the insurance we carry will     be sufficient</td>
    </tr>
    <tr>
      <td>A successful claim <font color="blue">against us</font> in excess of <font color="blue">insurance coverage</font>     could <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> us</td>
    </tr>
    <tr>
      <td>Furthermore, there is no assurance     that product <font color="blue">liability</font> insurance <font color="blue">will continue</font> to be available to us on     acceptable terms</td>
    </tr>
    <tr>
      <td>Our  Stockholder  Rights Plan, provisions in our <font color="blue">charter documents</font> and     <font color="blue">Delaware </font><font color="blue">law could prevent</font> or delay a change in control, <font color="blue">which could</font> reduce     the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>On July 15, 1997, our <font color="blue">Board of Directors </font>adopted a Stockholder Rights Plan     (the “Plan”) and, pursuant to the Plan, declared a dividend <font color="blue">distribution</font> of     one Right for each outstanding share of our <font color="blue">common stock</font> to <font color="blue">stockholders</font> of     record at the close of business on July 28, 1997</td>
    </tr>
    <tr>
      <td>Under its current provisions, each Right entitles the registered     holder to purchase from us one one-hundredth of a share of <font color="blue">Series A Junior     </font><font color="blue">participating</font> Preferred Stock, no par value, at <font color="blue">a Purchase Price </font>of dlra115 per     one one-hundredth of a share, subject to <font color="blue">adjustment</font></td>
    </tr>
    <tr>
      <td>The Plan is designed to     afford the Board a great deal of <font color="blue">flexibility</font> in dealing with any attempted     takeover  of and will cause <font color="blue">persons interested</font> in acquiring us to deal     <font color="blue">directly with</font> the Board, giving it an <font color="blue">opportunity</font> to negotiate a <font color="blue">transaction</font>     that <font color="blue">maximizes stockholder values</font></td>
    </tr>
    <tr>
      <td>The Plan may, however, have the effect of     <font color="blue">discouraging persons from attempting</font> to acquire us</td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font><font color="blue">should refer</font> to the description of the Plan in our <font color="blue">Current Report </font>    to <font color="blue">the Securities and Exchange Commission</font> on Form 8-K dated July 15, 1997     filed July 23, 1997, as updated by our <font color="blue">Current Report </font>dated January 30, 1999     filed <font color="blue">February </font>9, 1999, and the terms of the Rights set forth in an Amended     and Restated Rights Agreement, dated as of May 10, 2002 between                                           18     ______________________________________________________________________         ICU Medical, Inc</td>
    </tr>
    <tr>
      <td>and Mellon Investor Services, LLC, as Rights Agent,     which are filed as an exhibit to the May 14, 2002 Form 8-A/A         <font color="blue">Our Certificate of Incorporation and Bylaws </font>include provisions that may     discourage or <font color="blue">prevent certain types</font> of <font color="blue"><font color="blue">transaction</font>s</font> involving an actual or     potential  change  of  control,  including  <font color="blue"><font color="blue">transaction</font>s</font>  in which the     <font color="blue">stockholders</font> might otherwise receive a premium for their <font color="blue">shares over then</font>     current <font color="blue">market price</font>s</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Board of Directors </font>has the authority     to  <font color="blue">issue shares</font> of <font color="blue">Preferred Stock </font>and fix the rights and <font color="blue">preferences</font>     thereof, <font color="blue">which could</font> have the effect of delaying or preventing a change of     control  otherwise  desired  by the <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, certain     provisions of <font color="blue">Delaware </font>law may discourage, delay or prevent someone from     acquiring or <font color="blue">merging with us</font></td>
    </tr>
    <tr>
      <td>The  price  of our <font color="blue">common stock</font> has been and <font color="blue">may continue</font> to be highly     <font color="blue">volatile due</font> to many factors</td>
    </tr>
    <tr>
      <td>The market for small-market capitalization companies can be <font color="blue">highly volatile</font>,     and we have experienced <font color="blue">significant</font> <font color="blue">volatility</font> in the price of our common     stock in the past</td>
    </tr>
    <tr>
      <td>From the beginning of 2005 through January 2006, our     <font color="blue">trading price ranged from</font> a high of dlra43dtta09 per share to a low of dlra23dtta01 per     share</td>
    </tr>
    <tr>
      <td>We believe that factors such as quarter-to-quarter fluctuations in     financial results, differences between stock analysts’ expectations and     <font color="blue">actual quarterly</font> and annual results, <font color="blue">new product introductions</font> by us or our     <font color="blue">competitors</font>,  changing <font color="blue">regulatory</font> environments, <font color="blue">litigation</font>, changes in     healthcare reimbursement policies, sales or the <font color="blue">perception</font> in the market of     <font color="blue">possible sales</font> of <font color="blue">common stock</font> by insiders and substantial <font color="blue">product orders</font>     <font color="blue">could contribute</font> to the <font color="blue">volatility</font> in the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">General     </font><font color="blue">economic trends unrelated</font> to our <font color="blue">performance such as recessionary cycles</font> and     changing interest rates may also <font color="blue"><font color="blue">adversely</font> affect</font> the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">common stock</font> is held by, or included in <font color="blue">accounts</font> managed by,     <font color="blue">institutional</font> investors or managers</td>
    </tr>
    <tr>
      <td>Several of those <font color="blue">institutions</font> own or     manage a <font color="blue">significant</font> percentage of our <font color="blue">outstanding shares</font>, with the ten     largest interests <font color="blue">accounting</font> for 54prca of our <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>If one or     more of the <font color="blue">institutions</font> should decide to reduce or eliminate its position     in our <font color="blue">common stock</font>, it could cause a decrease in the price of the common     stock that could be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>For the past several years there has been a <font color="blue">significant</font> “short” position in     our <font color="blue">common stock</font>, consisting of borrowed shares sold, or shares sold for     future delivery which may not have been borrowed</td>
    </tr>
    <tr>
      <td>We do not know whether any     of these short positions are covered by “long” positions owned by the short     seller</td>
    </tr>
    <tr>
      <td>The short position, as reported by the Nasdaq <font color="blue">stock market on</font>     <font color="blue">February </font> 15,  2006  was 2cmam067cmam228 shares, or approximately 15prca of our     <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">attempt by</font> the short sellers to liquidate their     <font color="blue">position over</font> a short period of time could cause very <font color="blue">significant</font> <font color="blue">volatility</font>     in the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We have outstanding <font color="blue">stock options</font> which may dilute the ownership of existing     <font color="blue">shareholders</font>         At <font color="blue">December </font>31, 2005, we had outstanding <font color="blue">stock options</font> to purchase 4dtta0     <font color="blue">million shares</font>, of which 3dtta9 million had an <font color="blue">exercise price</font> below the market     price of our stock</td>
    </tr>
    <tr>
      <td>Exercise of those options would dilute the ownership     interest of existing <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Continued </font><font color="blue">compliance with</font> recent securities legislation could be uncertain     and could <font color="blue">substantially</font> increase our <font color="blue">administrative expenses</font></td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 imposed <font color="blue">significant</font> new <font color="blue">requirements</font> on     public companies</td>
    </tr>
    <tr>
      <td>We have <font color="blue">complied with most</font> of these <font color="blue">without undue effort</font>     or expense</td>
    </tr>
    <tr>
      <td>However, <font color="blue">compliance with</font> Section 404 of the Sarbanes-Oxley Act     of 2002 requiring <font color="blue">management</font> to document and report on the <font color="blue">effective</font>ness of     <font color="blue">internal controls</font> of financial reporting and our in<font color="blue">dependent</font> registered     public <font color="blue">accounting</font> firm to audit and report on the design and <font color="blue">effective</font>ness     of  our  internal  controls  of financial reporting has been extremely     expensive</td>
    </tr>
    <tr>
      <td>Further, there is <font color="blue">no certainty</font> that we <font color="blue">will continue</font> to receive     unqualified reports on our <font color="blue">internal controls</font> of financial reporting from our     in<font color="blue">dependent</font> registered public <font color="blue">accounting</font> firm and what <font color="blue">actions might</font> be     <font color="blue">taken by securities regulators</font> or investors if we are unable to obtain an     unqualified report</td>
    </tr>
  </tbody>
</table>